Affordable Access

deepdyve-link
Publisher Website

Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis

Authors
  • Kullberg, S.1, 2
  • Rivera, N. V.2
  • Abo Al Hayja, M.2
  • Grunewald, J.1, 2
  • Eklund, A.1, 2
  • 1 Karolinska University Hospital, Sweden , (Sweden)
  • 2 Karolinska Institutet, Sweden , (Sweden)
Type
Published Article
Journal
Clinical & Experimental Immunology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Apr 22, 2020
Volume
201
Issue
1
Pages
85–93
Identifiers
DOI: 10.1111/cei.13438
PMID: 32275772
PMCID: PMC7290087
Source
PubMed Central
Keywords
License
Unknown
External links

Abstract

Six months of infliximab treatment in patients with sarcoidosis led to signs of a decreased CD4+ T‐cell alveolitis in the lungs of responders. A significant decrease in CD4/CD8 ratio and percentage of CD4+ T‐cells expressing the activation marker CD69 was seen. Also, the number of mast cells decreased in responders.

Report this publication

Statistics

Seen <100 times